Positive News SentimentPositive NewsNASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis $3.40 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.40 0.00 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Minerva Neurosciences Stock (NASDAQ:NERV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Minerva Neurosciences alerts:Sign Up Key Stats Today's Range$3.23▼$3.4450-Day Range$3.40▼$5.4352-Week Range$2.06▼$12.46Volume62,249 shsAverage Volume212,952 shsMarket Capitalization$162.34 millionP/E RatioN/ADividend YieldN/APrice Target$10.33Consensus RatingReduce Company Overview Minerva Neurosciences, Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s research has centered on therapies for conditions with significant unmet medical needs, including schizophrenia, depression and other neuropsychiatric diseases. Minerva’s leading investigational product has been roluperidone, formerly known as MIN-101. The orally administered compound is designed to address negative symptoms of schizophrenia, such as social withdrawal, reduced motivation and diminished emotional expression. The company has evaluated roluperidone in clinical studies and has pursued regulatory review in the United States. Minerva Neurosciences was founded in 2013 and is based in Waltham, Massachusetts. Its development activities have involved clinical research conducted in the United States and Europe. The company has also advanced additional neuroscience programs at various stages of development, although its pipeline and strategic priorities may change as clinical and regulatory work progresses.AI Generated. May Contain Errors. Read More Minerva Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNERV MarketRank™: Minerva Neurosciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 724th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingReduce Consensus RatingMinerva Neurosciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.Upside PotentialMinerva Neurosciences has a consensus price target of $10.33, representing about 205.6% upside from its current price of $3.38.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 3 research reports in the past 90 days.Read more about Minerva Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.73) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Minerva Neurosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.16% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 20.13, which indicates bearish sentiment.Change versus previous monthShort interest in Minerva Neurosciences has recently increased by 14.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentMinerva Neurosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Minerva Neurosciences this week, compared to 2 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by Institutions34.56% of the stock of Minerva Neurosciences is held by institutions.Read more about Minerva Neurosciences' insider trading history. Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NERV Stock News HeadlinesMinerva Neurosciences to Participate in Two Upcoming Investor ConferencesAugust 28, 2026 | globenewswire.comMinerva Neurosciences Provides Second Quarter 2026 Financial Results and Business UpdatesAugust 7, 2026 | globenewswire.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 28 at 1:00 AM | TradeSmith (Ad)Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsJune 1, 2026 | globenewswire.comMinerva Neurosciences Launches ATM Offering to Fund TrialMay 27, 2026 | tipranks.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 18, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | finanznachrichten.deMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | globenewswire.comSee More Headlines NERV Stock Analysis - Frequently Asked Questions How have NERV shares performed this year? Minerva Neurosciences' stock was trading at $4.02 at the beginning of the year. Since then, NERV stock has decreased by 15.9% and is now trading at $3.3810. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc (NASDAQ:NERV) announced its earnings results on Friday, August, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. When did Minerva Neurosciences' stock split? Minerva Neurosciences shares reverse split on Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Minerva Neurosciences IPO? Minerva Neurosciences (NERV) raised $33 million in an initial public offering (IPO) on Thursday, June 26th 2014. The company issued 5,454,545 shares at a price of $6.00 per share. Who are Minerva Neurosciences' major shareholders? Minerva Neurosciences' top institutional investors include Seven Fleet Capital Management LP (2.10%) and Bank of New York Mellon Corp (0.16%). View institutional ownership trends. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/07/2026Today9/28/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, NERV's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NERV CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees7Year Founded2007Price Target and Rating Average Price Target for Minerva Neurosciences$10.33 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+203.9%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($28.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$293.42 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-31.72% Debt Debt-to-Equity RatioN/A Current Ratio20.15 Quick Ratio20.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.25) per share Price / Book-1.05Miscellaneous Outstanding Shares47,748,000Free Float46,936,000Market Cap$162.34 million OptionableNot Optionable Beta-0.08 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NERV) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
